Bosutinib

(Bosulif®)

Bosutinib

Drug updated on 11/8/2023

Dosage FormTablet (oral; 100 mg, 400 mg, 500 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
  • For the treatment of adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML).

Product Monograph / Prescribing Information

Document TitleYearSource
Bosulif (bosutinib) Prescribing Information.2023Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis. 2023Acta Oncologica
Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis. 2023Cancers
Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis. 2023Future Oncology
A systematic literature review of the economic evaluations of treatments for patients with chronic myeloid leukemia.2022PharmacoEconomics
A systematic literature review of the economic evaluations of treatments for patients with chronic myeloid leukemia.2022PharmaEconomic
Arterial hypertension and tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis.2021Frontiers in Pharmacology
Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia.2021JAMA Network Open
Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.2021Cancers
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. 2020Blood
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta‚Äźanalysis.2019The British Pharmacological Society
Assessment report: Bosulif.2018EMA
Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: a systematic review and network meta-analysis.2018European Journal of Cancer

Clinical Practice Guidelines